<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04203914</url>
  </required_header>
  <id_info>
    <org_study_id>CNO20168</org_study_id>
    <nct_id>NCT04203914</nct_id>
  </id_info>
  <brief_title>Short Term Effect of Empagliflozin in Hypertension</brief_title>
  <acronym>EMPHYT</acronym>
  <official_title>Short Term Effect of Empagliflozin on Left Ventricular Relaxation in Non Diabetic Hypertensive Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yaounde Central Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yaounde Central Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators assessed the 6-week effect of once daily 25mg SGLT2-i Empagliflozin on left
      ventricular diastolic function and blood pressure profile in non diabetic hypertensive
      patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: The rapid beneficial effects of Empagliflozin on cardiovascular mortality and
      hospitalizations rates for heart failure according to the Cardiovascular Outcome Event Trial
      in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME) trial raise some question in the
      mechanism of myocardial action. The investigators conducted this study in a population of
      non-diabetic hypertensive patients in order to look for a short-term effect on left
      ventricular relaxation.

      Methods: The investigators carried out a single arm non- randomized clinical trial and
      assigned patients to receive 25mg of empagliflozin once daily in additional therapy for six
      weeks at the National Center for Obesity and in the cardiology department of Yaounde Central
      Hospital in hypertensive patients with cardiac relaxation disorder. The objectives were to
      evaluate the left ventricular diastolic function and nycthemeral blood pressure profile.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 10, 2017</start_date>
  <completion_date type="Actual">September 30, 2017</completion_date>
  <primary_completion_date type="Actual">May 30, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open label trial with before and after design</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Left ventricular diastolic function</measure>
    <time_frame>6 weeks</time_frame>
    <description>Doppler ultrasound measured relaxation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>6 weeks</time_frame>
    <description>24-h ambulatory blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c</measure>
    <time_frame>6 weeks</time_frame>
    <description>Glycated haemoglobin</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Empagliflozin 25mg daily add-on therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin Tablets</intervention_name>
    <description>Add-on 25mg once daily</description>
    <arm_group_label>Intervention</arm_group_label>
    <other_name>SGLT2-i</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Grade 1 hypertension

          -  Grade 1 or 2 relaxation abnormalities (Doppler E/A ratio &lt;1)

          -  Unchanged antihypertensive treatment for at least 12 weeks

        Exclusion Criteria:

          -  Diabetes mellitus

          -  eGFR &lt; 60 mL/min/1,73 mÂ²

          -  Mitral stenosis

          -  Atrial fibrillation

          -  Alanine transferase above 2N
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean Claude Mbanya, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Yaounde 1, Cameroon</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eugene Sobngwi, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Yaounde 1, Cameroon</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Obesity Centre, Yaounde Central Hospital</name>
      <address>
        <city>Yaounde</city>
        <state>Centre</state>
        <country>Cameroon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yaounde Central Hospital</name>
      <address>
        <city>Yaounde</city>
        <state>Centre</state>
        <country>Cameroon</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Cameroon</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 17, 2019</study_first_submitted>
  <study_first_submitted_qc>December 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 18, 2019</study_first_posted>
  <last_update_submitted>December 18, 2019</last_update_submitted>
  <last_update_submitted_qc>December 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yaounde Central Hospital</investigator_affiliation>
    <investigator_full_name>Sobngwi Eugene</investigator_full_name>
    <investigator_title>Medical Advisor</investigator_title>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <keyword>Empagliflozin</keyword>
  <keyword>Left ventricular diastolic function</keyword>
  <keyword>Blood pressure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Centrally available database available on request</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>December 2019 for 5 years</ipd_time_frame>
    <ipd_access_criteria>Requirements of Cameroon Ethics authorities</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

